Cargando…
A tumor‐targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti‐PD‐1 immunotherapy in mouse models of glioblastoma
Despite its anticipated clinical potential, anti‐PD‐1 immunotherapy has only yielded poor outcomes in recent clinical trials for glioblastoma patients. Strategies combining anti‐PD‐1 antibody with other treatment modalities are being explored to alter the immunosuppressive microenvironment that appe...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771527/ https://www.ncbi.nlm.nih.gov/pubmed/31241175 http://dx.doi.org/10.1002/ijc.32531 |